Hospira highlights growth trends during 2012

Hospira has reported its financial results for the fourth quarter and full-year periods of 2012, during which it made significant progress towards its long-term growth objectives.

The company generated $1.089 billion (708.23 million pounds) in sales during the final three months of the year, up by 8.4 percent year on year, which contributed to a yearly total of $4.009 billion and annual growth of 0.9 percent.

Strong net sales of specialty injectable pharmaceutical products helped to contribute to this performance and allowed Hospira to meet its financial projections for the year, with efforts to improve its corporate efficiency also progressing well.

In 2013, the company expects to achieve net sales growth of between one and three percent for the full-year period.

F Michael Ball, chief executive officer of Hospira, said: "We will continue to advance our remediation activities as well as work to increase supply of the products our customers – and their patients – depend on. At the same time, we are forging ahead with our growth expansion initiatives."

Hospira is the world's leading provider of injectable drugs and infusion technologies, with a global footprint covering five continents and more than 70 countries.